

Matthew W Mccarthy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4049400/publications.pdf>

Version: 2024-02-01

57
papers

1,051
citations

516215

16
h-index

433756

31
g-index

61
all docs

61
docs citations

61
times ranked

1486
citing authors

#	ARTICLE	IF	CITATIONS
1	Mold Infections of the Central Nervous System. <i>New England Journal of Medicine</i> , 2014, 371, 150-160.	13.9	157
2	Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. <i>Journal of Infectious Diseases</i> , 2017, 216, S474-S483.	1.9	135
3	Cefiderocol: a novel siderophore cephalosporin. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 193-197.	1.9	57
4	Recent Advances in the Treatment of Scedosporiosis and Fusariosis. <i>Journal of Fungi (Basel,)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 T	1.5	49
5	<i>In Vitro</i> Combination of Isavuconazole with Micafungin or Amphotericin B Deoxycholate against Medically Important Molds. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6934-6937.	1.4	39
6	Drug development challenges and strategies to address emerging and resistant fungal pathogens. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 577-584.	2.0	38
7	PCR methodology and applications for the detection of human fungal pathogens. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1025-1036.	1.5	36
8	Novel applications for serum procalcitonin testing in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 27-34.	1.5	35
9	Fungal Infections of the Central Nervous System in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, e123-e133.	0.6	33
10	Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1483-1491.	1.6	32
11	Emerging drugs and vaccines for Candidemia. <i>Mycoses</i> , 2014, 57, 718-733.	1.8	31
12	Drugs currently under investigation for the treatment of invasive candidiasis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 825-831.	1.9	27
13	Future Research Priorities in Fungal Resistance. <i>Journal of Infectious Diseases</i> , 2017, 216, S484-S492.	1.9	26
14	Amino Acid Metabolism and Transport Mechanisms as Potential Antifungal Targets. <i>International Journal of Molecular Sciences</i> , 2018, 19, 909.	1.8	26
15	Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial. <i>Infectious Diseases and Therapy</i> , 2020, 9, 53-67.	1.8	26
16	The expanding use of matrix-assisted laser desorption/ionization-time of flight mass spectroscopy in the diagnosis of patients with mycotic diseases. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 241-248.	1.5	25
17	OUP accepted manuscript. <i>Medical Mycology</i> , 2017, 55, 859-868.	0.3	19
18	Molecular diagnosis of invasive mycoses of the central nervous system. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 129-139.	1.5	16

#	ARTICLE	IF	CITATIONS
19	Translational Development and Application of (1 ³ C)-β-D-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1124.	1.8	16
20	Teixobactin: a novel anti-infective agent. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 1-3.	2.0	15
21	Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy. <i>Clinical Pharmacokinetics</i> , 2020, 59, 567-573.	1.6	15
22	Pharmacokinetics and Pharmacodynamics of Ibrexafungerp. <i>Drugs in R and D</i> , 2022, 22, 9-13.	1.1	15
23	Candidemia in the cancer patient: diagnosis, treatment, and future directions. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 849-854.	2.0	14
24	Prophylactic Measures During Induction for Acute Myeloid Leukemia. <i>Current Oncology Reports</i> , 2017, 19, 18.	1.8	13
25	Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	12
26	Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1149-1153.	1.6	12
27	Nucleic acid amplification methodologies for the detection of pulmonary mold infections. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 271-279.	1.5	11
28	Diagnosis, classification, and therapeutic interventions for sinopulmonary Aspergillosis. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 229-238.	1.0	10
29	Teaching Clinical Ethics at the Bedside: William Osler and the Essential Role of the Hospitalist. <i>AMA Journal of Ethics</i> , 2017, 19, 528-532.	0.4	9
30	At-home coronavirus testing: the next game-changer?. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1-2.	1.5	9
31	Combination therapy for the treatment of pulmonary mold infections. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 481-489.	1.0	8
32	Containment strategies to address the expanding threat of multidrug-resistant <i>Candida auris</i> . <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 1095-1099.	2.0	8
33	Outpatient treatment options to address the SARS-CoV-2 variant Omicron. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1129-1133.	2.0	8
34	Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 739-748.	1.0	7
35	Frequency of Ethical Issues on a Hospitalist Teaching Service at an Urban, Tertiary Care Center. <i>Journal of Hospital Medicine</i> , 2019, 14, 290-293.	0.7	7
36	Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 799-805.	2.0	6

#	ARTICLE	IF	CITATIONS
37	The Diagnostic Accuracy Of Procalcitonin for Urinary Tract Infection in Hospitalized Older Adults: a Prospective Study. <i>Journal of General Internal Medicine</i> , 2022, 37, 3663-3669.	1.3	6
38	The rise of hospitalists: an opportunity for infectious diseases investigators. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 385-389.	2.0	5
39	Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19). <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 623-628.	0.9	5
40	Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections. <i>Drugs in R and D</i> , 2022, 22, 113-117.	1.1	5
41	Emerging diagnostic and therapeutic options for treating mucormycosis. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1253-1261.	0.5	4
42	Galactomannan antigenemia as a biomarker for therapeutic response of invasive aspergillosis: implications for clinical trial design and patient care. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 601-604.	1.5	4
43	Efficacy of Amphotericin B in Corneal Preservation Media After Extended Frozen Storage. <i>Cornea</i> , 2020, 39, 1274-1277.	0.9	4
44	Checkpoint inhibitors and the risk of infection. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 287-293.	0.4	3
45	The prognostic value of mid-regional pro-adrenomedullin in the evaluation of acute dyspnea. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 147-153.	1.5	3
46	The Rise of Hospitalists: An Opportunity for Clinical Ethics. <i>Journal of Clinical Ethics</i> , 2017, 28, 325-332.	0.1	3
47	Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1387-1394.	1.6	2
48	Use of a Commercial HIV Co-Receptor Tropism Assay in Clinical Practice. <i>AIDS Patient Care and STDs</i> , 2015, 29, 53-54.	1.1	1
49	Harnessing the potential of CRISPR-Cas9 to advance the study of human fungal pathogens. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 295-301.	0.4	1
50	The surviving sepsis controversy: a call to action for hospital medicine. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 889-892.	2.0	1
51	Ethical challenges of prospective clinical trials during the COVID-19 pandemic. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 549-554.	2.0	1
52	Fluticasone propionate as a potential treatment for COVID-19. <i>Drugs of Today</i> , 2022, 58, 241-247.	0.7	1
53	The fungal meningitis outbreak five years later: what have we learned about <i>Exserohilum rostratum</i> ?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 321-325.	0.4	0
54	Procalcitonin utilization in the real world: An observational study of antibiotic prescribing practices. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 1220-1223.	0.9	0

#	ARTICLE	IF	CITATIONS
55	11010 The diagnostic accuracy of procalcitonin for urinary tract infection in hospitalized older adults. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 28-29.	0.3	0
56	The Great Gatsby and the challenge of unreliable narrators. <i>Lancet, The</i> , 2021, 398, 203.	6.3	0
57	279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry. <i>Open Forum Infectious Diseases</i> , 2020, 7, S140-S140.	0.4	0